![](/images/graphics-bg.png)
Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors
المؤلفون المشاركون
Grandis, Jennifer Rubin
Egloff, Ann Marie
المصدر
العدد
المجلد 2009، العدد 2009 (31 ديسمبر/كانون الأول 2009)، ص ص. 1-12، 12ص.
الناشر
Hindawi Publishing Corporation
تاريخ النشر
2009-07-14
دولة النشر
مصر
عدد الصفحات
12
التخصصات الرئيسية
الملخص EN
The epidermal growth factor receptor- (EGFR-) directed antibody, cetuximab, was FDA-approved for the treatment of squamous cell carcinoma of the head and neck (SCCHN) in 2006.
Additional EGFR-targeting agents in clinical development for SCCHN include other EGFR-directed antibodies, tyrosine kinase inhibitors and antisense DNA.
Although the majority of SCCHN overexpress EGFR, SCCHN clinical responses to EGFR-targeting agents have been modest.
Molecular predictors for SCCHN response to EGFR-targeted therapies have not been identified.
However, molecular correlate studies in lung cancer and colon cancer, which have EGFR-targeted therapeutics FDA-approved for treatment, may provide insights.
We describe candidate predictive markers for SCCHN response to EGFR-targeted therapies and their prevalence in SCCHN.
Clinical response will likely be improved by targeted therapy combination treatments.
Src family kinases mediate EGFR-dependent and -independent tumor progression pathways in many cancers including SCCHN.
Several Src-targeting agents are in clinical development for solid malignancies.
Molecular correlate studies for Src-targeting therapies are few and biomarkers correlated with patient response are limited.
Identifying SCCHN patients who will respond to combined EGFR- and Src-targeting will require further characterization of molecular correlates.
We discuss rationale for EGFR and Src co-targeting for SCCHN treatment and describe recent clinical trials implementing combined Src- and EGFR-targeted therapeutics.
نمط استشهاد جمعية علماء النفس الأمريكية (APA)
Egloff, Ann Marie& Grandis, Jennifer Rubin. 2009. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology،Vol. 2009, no. 2009, pp.1-12.
https://search.emarefa.net/detail/BIM-506274
نمط استشهاد الجمعية الأمريكية للغات الحديثة (MLA)
Egloff, Ann Marie& Grandis, Jennifer Rubin. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology No. 2009 (2009), pp.1-12.
https://search.emarefa.net/detail/BIM-506274
نمط استشهاد الجمعية الطبية الأمريكية (AMA)
Egloff, Ann Marie& Grandis, Jennifer Rubin. Improving Response Rates to EGFR-Targeted Therapies for Head and Neck Squamous Cell Carcinoma : Candidate Predictive Biomarkers and Combination Treatment with Src Inhibitors. Journal of Oncology. 2009. Vol. 2009, no. 2009, pp.1-12.
https://search.emarefa.net/detail/BIM-506274
نوع البيانات
مقالات
لغة النص
الإنجليزية
الملاحظات
Includes bibliographical references
رقم السجل
BIM-506274
قاعدة معامل التأثير والاستشهادات المرجعية العربي "ارسيف Arcif"
أضخم قاعدة بيانات عربية للاستشهادات المرجعية للمجلات العلمية المحكمة الصادرة في العالم العربي
![](/images/ebook-kashef.png)
تقوم هذه الخدمة بالتحقق من التشابه أو الانتحال في الأبحاث والمقالات العلمية والأطروحات الجامعية والكتب والأبحاث باللغة العربية، وتحديد درجة التشابه أو أصالة الأعمال البحثية وحماية ملكيتها الفكرية. تعرف اكثر
![](/images/kashef-image.png)